NCT07175415 - HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2026

Primary Completion Date

October 1, 2031

Study Completion Date

October 1, 2032

Conditions

Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Interventions

DRUG

Capivasertib

Oral

DRUG

Venetoclax

Oral

DEVICE

Dexamethasone

oral/intravenous

DRUG

Intrathecal chemotherapy

IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement